OTTN attends ACCT conference

The Alliance for Commercialization of Canadian Technologies (ACCT) held its 5th Annual Meeting in beautiful Victoria from November 8-10.  Joe Irvine, Sean Flanigan, and Brian Julien from OTTN attended the conference which focused on positive trends and future opportunities to overcome the current challenges faced by institutional research and the technology transfer profession. ACCT promotes world class technology transfer and commercialization for the benefit of Canadians.

Joe Irvine was moderator for the track “Lean, Mean, Green and Clean: Exploring Opportunities to Make Money in an Emerging Carbon Economy”

Sean Flanigan was panelist for the track “Streamlining Inter-Institutional Agreements: Diminishing the Pain and Increasing the Gain”

Two noteworthy announcements were made at the conference.  Joe Irvine was appointed to the Board of Directors of ACCT  and the 2010 ACCT conference will be held in Ottawa and co-chaired by Sean Flanigan.

Learn more on ACCT >
ACCT 2009 conference Agenda >
ACCT 2009 Conference materials >

Jennerex receives orphan drug designation

Established in 2006, in San Francisco (US) and in Ottawa (Canada) with Dr. David Kirn as CEO and Dr. John Bell from the Ottawa Health Research Institute/University of Ottawa as CSO, Jennerex Biotherapeutics was granted by European Medicines Agency (EMEA) the Orphan Drug Designation to Jennerex’s product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

Read more on Jennerex news >